A Comprehensive Review of Immunosuppression Used for Liver Transplantation by Mukherjee, Sandeep & Mukherjee, Urmila
Hindawi Publishing Corporation
Journal of Transplantation
Volume 2009, Article ID 701464, 20 pages
doi:10.1155/2009/701464
Review Article
A Comprehensive Review of Immunosuppression Used for
Liver Transplantation
SandeepMukherjee1 andUrmilaMukherjee2
1Section of Gastroenterology and Hepatology, University of Nebraska Medical Center, Omaha, NE 68198-3285, USA
2Southampton University Hospital Trust, Tremona Road, Southampton, New Hampshire SO16 6YD, UK
Correspondence should be addressed to Sandeep Mukherjee, smukherj@unmc.edu
Received 16 April 2009; Accepted 15 May 2009
Recommended by A. Joseph Tector
Since liver transplantation was approved for the treatment of end stage liver disease, calcineurin inhibitors (CNI’s) have played
a critical role in the preservation of allograft function. Unfortunately, these medications cause a variety of Side eﬀects such as
diabetes, hypertension and nephrotoxicity which in turn result in signiﬁcant morbidity and reduced quality of life. A variety of
newer immunosuppressants have been evaluated over the last decade in an attempt to either substitute for CNI’s or use with
reduced dose CNI’s while still preserving allograft function However, current data does not recommend complete cessation
of CNI’s due to unacceptably high rates of allograft rejection. As these medications have their own unique adverse eﬀects, a
careful assessment on their risks and beneﬁts is essential, particularly when additive or synergistic eﬀects with CNI’s may occur.
Furthermore,theimpactofthesenewermedicationsontheriskofhepatitisCrecurrenceandprogressionremainstobeelucidated.
Controlled trials are urgently required to assist transplant physicians with choosing the optimum immunosuppressive regimen
for their patients. This review will discuss commonly used immunosuppressants prescribed in liver transplantation, emerging
therapties and where appropriate, the impact of these medications on the recurrence of hepatitis C after liver transplantation.
Copyright © 2009 S. Mukherjee and U. Mukherjee. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
In the early 1980’s, two sentinel events heralded a new era
in liver transplantation. The ﬁrst was the introduction of
Cyclosporine (Csa) in 1981 which revolutionized immuno-
suppression (IS) by drastically reducing the incidence of
allograft rejection when combined with corticosteroids (CS)
and azathioprine (AZA). This was followed by a pivotal con-
sensus meeting at the National Institutes of Health in 1983
which approved liver transplantation (LT) for the treatment
of end stage liver disease [1, 2]. In 1994, a landmark study
by the US multicenter FK506 Liver Study Group comparing
Csa with tacrolimus reported that although survival with
both drugs was similar, tacrolimus was associated with fewer
episodes of steroid-resistant rejection at a cost of increased
adverse events such as nephrotoxicity and neurotoxicity [3].
Rejection which was reported to be an important cause of
death in this study has now become more manageable due
to the development of newer and more potent immunosup-
pressants such that overimmunosuppression has become a
greater cause of concern.
The optimal IS regimen remains the holy grail of organ
transplantation until tolerogenic interventions succeed, that
is, the level of drug therapy which leads to graft acceptance
with least suppression of systemic immunity. This approach
is further complicated by a lack of standardization in
IS between transplant programs and the management of
chronic and, to a lesser extent, acute cellular rejection (ACR)
[4]. Current protocols use a combination of drugs with
diﬀerent modes of action and toxicities directed at speciﬁc
sites of the T-cell activation cascade, thus allowing lower
doses of each drug [5]. Induction therapy refers to the
practice of administering potent antibody therapy in the
perioperative period (when the risk of allograft rejection
is greatest) and delaying the introduction of maintenance
therapy such as calcineurin inhibitors (CNI’s) which have2 Journal of Transplantation
been the backbone of most immunosuppressive regimens in
LT. Due to the well-known adverse eﬀects of long-term CNI
use, alternative strategies such as CNI minimization or even
complete avoidance have been attempted [6–8]. The process
of ACR and T cell activation will be brieﬂy reviewed before
discussing immunosuppressive drugs used in LT.
2.AcuteCellularRejection
ACR is a complex process comprised of the following steps:
alloantigen recognition, T-cell activation, clonal expansion,
and graft inﬂammation.
2.1.AllograftRecognition. Foreign(orallo-)antigensarepre-
sented to lymphocytes by antigen-presenting cells (APC’s)
such as dendritic cells. After LT, these antigens are shed
into the circulation and presented to secondary lymphoid
organs such as the spleen and regional lymph nodes. Naive
lymphocytes home to these secondary lymphoid organs
via speciﬁc receptors and encounter APC’s [9, 10]. This
process is aborted by antilymphocyte antibodies. APC’s
enzymatically process foreign proteins and load them onto
major histocompatibility complex (MHC) molecules, which
are displayed on the cell surface to T cells. The T-cell
receptor (TCR) is the antigen-recognition unit on the T-
cell surface and associated with molecules such as Cluster
of Diﬀerentiation 3 (CD3) and either CD4 or CD8 [11].
The TCR-CD3 complex interacts with the peptide fragment
carried by the MHC molecule of the APC is stabilized by
the CD4 or CD8 molecule and results in Signal 1 of T-cell
activation, a calcium-dependent pathway which is unable to
activate naive T cells independently.
2.2. T-Cell Activation. Signal 2 is a calcium-independent
pathway that represents the binding of costimulatory
molecules on T cells such as CD28 receptor with their
ligands found on APC’s which include but are not limited
to molecules such as B7.1 (CD80), B7.2 (CD86), and
CD40/CD40L (or CD154). Both signals 1 and 2 are required
for naive T-cell activation which is primarily mediated by
calcineurin, protein kinase C and zeta-associated protein-
70 activation of NF-AT, NF-κB, and AP-1, respectively [12].
Thesecytoplasmicfactorstranslocatetothenucleusandbind
to various gene promoters associated with T-cell activation
and proliferation, particularly interleukin-2 (IL-2). This
initiates the G0 to G1 transition of the cell cycle which results
in T-lymphocyte activation which can be arrested by CNI’s
such as Csa and tacrolimus.
2.3. Clonal Expansion. Signal 3 of T-cell activation results
from autocrine and paracrine cytokine-mediated signalling
via speciﬁc cytokine receptors. The IL-2 receptor family
includes receptors for IL-2, IL-4, IL-7, IL-12, and IL-15 and
share a common gamma-chain but diﬀer in composition
of the alpha and beta chains. In T cells, IL-2 binds to the
gamma-chain of the IL-2 receptor and activates the Janus
kinases (JAK) 1 and 3. This in turn triggers a cascade of
intracellular signalling pathways such as signal transducers
and activators of transcription (STAT) 5, Ras-Raf-MAP
kinase, and mTOR/P13-K/p70 S6 kinase activation. This
results in cell proliferation, deoxyribonucleic acid (DNA)
synthesis, and cell division as demonstrated by transition of
the cell cycle from G1 to the S phase. This important pathway
can be interrupted by AZA, mycophenolate mofetil (MMF),
sirolimus, and everolimus.
2.4. Inﬂammation. T cell activation and proliferation results
in the release of a variety of cytokines which in turn
recruit cytotoxic T cells, activated macrophages and B cells,
chemokines, and adhesion molecules. A variety of cell
adhesion molecules such as CD2, LFA-1, and VLA-4 are
also activated while L-selectin is downregulated. The net
eﬀect of these processes is to create an inﬂammatory milieu
by developing an environment which attracts activated T
cells. Cell damage and death arises from the production
of vasoactive and toxic mediators from activated T cells
such as tumor necrosis factor-alpha (TNF-alpha), TNF-beta
(also known as lymphotoxin), as well as cytotoxins, such
as perforin and granzymes, a family of serine proteases
and enhanced Fas ligand expression. This process may be
inhibited by CS and antilymphocyte antibodie.
3. ImmunosuppressiveAgents
Immunosuppressive medications can be classiﬁed in a vari-
ety of ways-induction versus maintenance, biologic versus
pharmacologic, mechanism of action, and/or site of signal,
pathway interruption (Table 1). Biologic agents are often
used for induction and include antilymphocyte antibodies
(mono- and polyclonal) and anticytokine receptor antibod-
ies. Pharmacologic immunosuppression includes virtually
all the other immunosuppressants used for maintenance
therapy such as CS, CNI’s which act by suppressing cytokine
release and cell cycle inhibitors (AZA, MMF, sirolimus,
everolimus).
Inhibitors of the Signal 1 pathway include agents that
aﬀect T-cell recognition of alloantigen and signal trans-
duction via the calcium-dependent calcineurin pathway.
Signal 2 inhibitors inhibit costimulatory pathways, and
Signal 3 inhibitors inhibit cytokine-driven proliferation.
Finally, other agents inhibit a variety of other points in the
immune system such as antimetabolites that interfere with
DNA and ribonucleic acid (RNA) replication or lymphocyte
traﬃcking, and investigational agents whose mechanism of
action has not fully determined.
4. Use of ImmunosuppressiveAgents in
LiverTransplantationinthe UnitedStates
The Scientiﬁc Registry of Transplant Recipients recently
reported the nature of the use of IS in the United States by
analyzing the United Network of Organ Sharing database
[13, 14]. Induction antibody use was noted in 18% of LT,
the majority of which were IL-2 receptor antibodies and
the remainder being antithymocyte globulins. CNI use was
reported in 97% of patients discharged from the hospitalJournal of Transplantation 3
Table 1: Commonly used immunosuppressive agents in liver
transplantation and their target pathways.
Immunosuppressive agent Target pathway
Pharmacological
Corticosteroids
(a) Inhibits cytokine
transcription by antigen
presenting cell
(b) Selective lysis of immature
cortical thymocytes
Calcineurin inhibitors
(cyclosporine/neoral and
tacrolimus/Prograf/Fk506)
Inhibits Signal 2 transduction
via T cell receptor
Mammalian Target of
rapamycin inhibitors
(sirolimus/rapamycin,
everolimus)
Inhibits signal 3 transduction
via IL-2 receptor
Azathioprine (Imuran) Inhibits purine and DNA
synthesis
Mycophenolic acid (cell
cept)
Inhibits purine and DNA
synthesis
Biological
Anti-CD3 monoclonal
antibodies (OKT3)
(a) Causes depletion and
receptor modulation in T cell
(b) Interferes with signal 1
Antithymocyte globulin
(ATG)
(a) Causes depletion and
receptor modulation in T cells
(b) Interferes with signal 1, 2
and 3
(c) Inhibits lymphocyte
traﬃcking
Anti IL-2 alpha chain
receptor antibodies
(Basiliximab,
Daclizumumab)
Inhibits T cell proliferation to
IL-2 (signal 3)
Anti-CD52 monoclonal
antibodies (campath 1-H)
Causes depletion of thymocytes,
T cells, B cells (not plasma cells)
and monocytes
after LT in the United States in 2002 while CS use was
reported in more than 90% of patients. At discharge, MMF
was noted in nearly 48%, AZA in 4% at discharge, and
rapamycin in nearly 7% of LT. The popularity of CNI is not
only a testament of the eﬀectiveness of these medications
in liver transplant recipients but also provides transplant
professionals an opportunity to perform well-designed trials
usingCNI-freeISinanattempttoavoidthelong-termeﬀects
of CNI toxicity after LTX. Immunosuppressive medications
used in LT will now be reviewed and appropriate drug
interactions will be discussed.
5. CalcineurinInhibitors—Cyclosporine
andTacrolimus
5.1. Background. Cyclosporine (Neoral, Novartis) is a cyclic
polypeptide comprised of 11 amino acids (molecular weight
1202.61) and was derived from the fungus Tolypocladium
inﬂatum in 1972. Csa’s immunosuppressive activity was
ﬁrst discovered in 1976 by Borel et al. who noted an
absence of myelotoxicity, a common complication of earlier
immunosuppressants [15]. One-year survival following LT
was only 26% in 1980 but the introduction of Csa the
following year proved to be a breakthrough in IS and led to
itsapprovalforuseinorgantransplantationin1982[16–18].
The impact of Csa after LT was conﬁrmed in a retrospective
study in which one- and ﬁve-year survival was 70 and 63%
whereas survival with conventional IS using prednisone and
AZA was 33 and 20%, respectively [19].
Tacrolimus (Prograf, FK506, Astellas Pharmaceuticals)
is a macrolide compound with a unique hemiketal-masked
alpha, beta diketoamide moiety in it structure. It is derived
from the fermentation products of fungus Streptomyces
tsukabaensis and which was discovered by the Fujisawa
Pharmaceutical Company in 1984 following analysis of soil
samples from Mount Tsukuba in Japan [20]. It was approved
for use in LT in the United States in 1994.
5.2.MechanismofAction. Csaandtacrolimusarecalcineurin
inhibitors that bind to their speciﬁc immunophilins,
cyclophilin and FK binding protein, respectively, before the
drug-receptor complex binds to and inhibits calcineurin,
a calcium-dependent phosphatase. Both immunophilins
have peptidy-prolyl-cis-trans isomerase activity although
this activity is not believed to be related to the immuno-
suppressive activity of the CNI-immunophilin complex. Csa
and tacrolimus are responsible for the dephosphorylation
of a variety of transcription factors, particularly nuclear
factor of activated T cells (NF-AT), a relatively lymphocyte-
speciﬁc cyoplasmic-based transcription factor. NF-AT sites
are present in the promoter regions of important cytokines
such as IL-2, IL-3, IL-4, granulocyte-macrophage colony
stimulating factor, interferon gamma (INF-gamma), and
TNF-alpha which are critical in the eﬃcient transcription
of these cytokine genes in response to activating signals
through the T cell receptor. Transforming growth factor beta
transcription is alsoincreased withCNI usewhichmay aﬀect
the development of ﬁbrosis in transplanted livers. CNI’s
therefore act primarily by interfering with Signal 2 of T-
cell activation. Experimental evidence also suggests that the
eﬀectivenessofCsaisduetospeciﬁcandreversibleinhibition
of immunocompetent lymphocytes in the G0- or G1-phase
of the cell cycle.
5.3. Pharmacokinetics and Pharmacodynamics. Csa was orig-
inally formulated as Sandimmune, a corn oil-based prepa-
ration limited by variable absorption, particularly in the
presence of cholestasis. This led to the development and
virtually universal adoption of Neoral, a nonaqueous,
microemulsiﬁed version, by most LT programs. Csa is
variablyabsorbedfromthejejunumandentersthelymphatic
system. Csa can be administeerd intravenously at a dose
approximately 30% of the oral dose. Peak concentrations in
blood and plasma are achieved at about 3.5 hours. Csa is
distributed largely outside the blood volume with concen-
trations greatest in adipose, adrenal, hepatic, pancreatic and4 Journal of Transplantation
renal tissues. In blood, Csa distribution is concentration–
dependent (33–47% is in plasma, 4–9% in lymphocytes,
5–12% in granulocytes, and 41–58% in erythrocytes) with
uptake by erythocytes and leucocytes saturated at higher
concentration. In plasma, approximately 90% is bound to
proteins, primarily lipoproteins.Csa elimination in blood is
biphasic with a half-life of approximately 18 hours (range: 10
to 27hours). Elimination is primarily biliary with only 6% of
the dose excreted in the urine.
Csa is extensively metabolized by the cytochrome P450
3A4 system into metabolites that have virtually no immuno-
suppressive activity. However, any drug that interacts with
the P450 pathway can inﬂuence Csa levels. Only 0.1% of
the dose is excreted in the urine as unchanged drug. Of 15
metabolites characterized in human urine, only nine have
been assigned structures.
Tacrolimus is approximately 100 times more potent than
Csa. Oral bioavailability is variable (5–67%) with the rate
and extent of absorption greatest under fasting conditions.
The presence and composition of food decreases the rate and
extent of absorption with the eﬀect most pronounced with a
high-fat- meal mean area under the curve (AUC) and peak
concentration were reduced by 37% and 77%, respectively.
A high-carbohydrate meal decreased mean AUC by 28%.
Tacrolimus has a half-life between 31.9 to 48.1 hours and a
volume of distribution about 0.85 to 1.94liters per kilogram
(L/kg). Protein binding is about 99%, mainly to albumin and
alpha-1 acid glycoprotein. Like Csa, tacrolimus is extensively
metabolized by the cytochrome CYP-450 3A4 system with
13-demethyl tacrolimus identiﬁed as the major metabolite.
Less than 1% of an administered dose is excreted unchanged
in the urine.
5.4. Side Eﬀects. T h em a i ns i d ee ﬀects of Csa and tacrolimus
are hypertension, nephrotoxicity, neurotoxicity, and lipid
abnormalities giving rise to an increased risk of death
from cardiovascular complications. Gingival hyperplasia and
hirsutism are associated with Csa whereas diabetes is more
common with tacrolimus. It has been suggested that the
inherent CNI properties of Csa and tacrolimus are linked
to nephrotoxicity although recent data suggest inhibition of
peptidyl-prolyl-cis trans-isomerase activity may account for
nephrotoxicity [21].
5.5. Drug Interactions. The following medications include
common examples of drug interaction with CNI’s and is
not a complete list. Examples of some common medications
which inhibit the P450 pathway and therefore increase Csa
levels include: calcium channel blockers (diltiazem, vera-
pamil, nicardipine); antibiotics (erythomycin, azithromycin,
clarithromycin,quinopristin/daltopristin); antifungals (ﬂu-
conazole, itraconazole, ketoconazole); amiodarone; allopuri-
nol; bromocriptine; colchicines and metoclopramide.
Protease inhibitors used for treating human immun-
odeﬁcieny virus (e.g., indinavir, nelﬁnavir, ritonavir, and
saquinavir) are known to inhibit cytochrome P-450 3A and
thus could potentially increase the concentrations of Csa.
However no formal studies of the interaction are available.
Care should be exercised when these drugs are administered
concomitantly. Grapefruit and grapefruit juice also increase
blood concentrations of Csa and should be avoided.
Examples of some common drugs and dietary supple-
mentsthatdecreaseCNIlevelsinclude:antibiotics(rifampin,
nafcillin); anticonvulsants (carbamazepine, phenobarbital,
phenytoin);octreotide;orlistat;sulphinpyrazone;terbinaﬁne
and ticlodipine. There have been reports of a serious drug
interaction between Csa and the herbal dietary supplement,
Saint. John’s Wort [22]. This interaction has been reported
to produce a marked reduction in the blood concentrations
of Csa, resulting in subtherapeutic levels, rejection of trans-
planted organs, and graft loss.
Rifabutin is known to increase the metabolism of other
drugs metabolized by the cytochrome P-450 system. The
interaction between rifabutin and Csa has not been well
studied but care should be exercised when these two drugs
are administered concomitantly.
5.6. Clinical Use in Liver Transplantation. The incremental
improvement in patient and graft survival seen with the
introduction of Csa in LT was far more dramatic than
the improvement seen with the introduction of tacrolimus
[23]. Three prospective, randomized controlled trials have
reported a signiﬁcantly lower incidence of rejection with
tacrolimus yet no signiﬁcant diﬀerence in one year patient
or graft survival [3, 24, 25]. One criticism of these early
studies was their use of oil-based (Sandimmune, Sandoz) as
opposed to the microemulsiﬁed version (Neoral, Novartis),
raising concerns of bioavailability versus eﬃcacy. However,
a landmark study by O’Grady et al. appeared to shed some
clarity on which CNI might have a greater impact on
graft and patient survival [26] .T h ep r e l i m i n a r yo n ey e a r
ﬁndings found tacrolimus more beneﬁcial after primary liver
transplants in adults with respect to freedom from graft
loss and immunological failure. The ﬁnal data after three
years conﬁrmed the signiﬁcant diﬀerence between Csa and
tacrolimus although freedom from death or retransplanta-
tion no longer achieved statistical signiﬁcance (relative risk
0.79; 95% Conﬁdence interval CI 0.62–1.02; P = .065). A
total of 62.1% of patients randomized to tacrolimus were
alive at theee years with their original graft and allocated
study medication compared to 41.6% in the Csa limb
(P<. 001). A further important ﬁnding of the study
was the observation no diﬀerence was detected between
tacrolimus and Csa in hepatitis C- (HCV-) positive patients.
These ﬁndings were supported in a meta-analysis com-
paring cyclosporine versus tacrolimus for liver transplant
patients [27, 28]. Tacrolimus was superior with respect
to patient and graft survival at one year, acute cellular
rejection, and steroid resistant rejection. The incidence of
lymphoproliferative disease and requirement for dialysis
was similar between both groups while diabetes mellitus
more common in the tacrolimus group. The investigators
also reported more patients stopped Csa than tacrolimus
and treating 100 recipients with tacrolimus instead of Csa
would prevent rejection and steroid-resistant rejection in
nine and seven patients, respectively, and graft loss andJournal of Transplantation 5
death in ﬁve and two patients, respectively. However, four
additional patients would develop diabetes after LT due
to the diabetogenic properties of tacrolimus compared to
Csa.
The impact of CNI’S on the natural history of recurrent
HCV has gained renewed interest after recent in vitro studies
showing an antiviral eﬀect of Csa on HCV replication in
the replicon system [29]. This was supported by a retro-
spective study comparing Csa with tacrolimus in patients
who received interferon-based therapy for recurrent HCV
[30] .P a t i e n t st r e a t e dw i t hC s a( 4 6 % )w e r em o r el i k e l yt o
achieve sustained viral response versus patients treated with
tacrolimus (27%) (P = .03). In addition, not only did
Csa inhibit HCV replication in a dose-dependent manner
but when combined with interferon had an additive eﬀect
independent of interferon signalling. Although there was no
statistically signiﬁcant diﬀerence in patient survival between
the two groups, Csa-treated patients had a lower baseline
HCV RNA and more episodes of acute cellular rejection
requiring steroid treatment. However, these ﬁndings have
not been reproduced in randomized, controlled prospective
studies. A recent meta-analysis reported similar rates of
ﬁbrosis and patient and graft survival at one year regard-
less of which calcineurin inhibitor was chosen [31]. The
diabetogenic impact of tacrolimus on the natural history of
recurrent HCV remains a concern, although a recent study
showed no diﬀerence in outcomes in Csa versus tacrolimus-
treated HCV patients at three years [26]. Currently, a
randomized controlled prospective study comparing Csa
versus tacrolimus incorporating serial liver biopsies and
HCV-RNA levels is underway but until these results are
available, it seems reasonable to state that current evidence
does not support a beneﬁcial eﬀect of Csa over tacrolimus on
HCV recurrence.
6.Corticosteroids
6.1. Background. Corticosteroids (CS) remain the most
widely used non-CNI immunosuppressant in LT. After
early pioneering studies showed CS could prolong skin
graft survival in rabbits, Starzl et al. and Murray et al.
independently demonstrated in 1963 that CS with AZA
could extend patient and allograft graft survival after human
allograft renal transplantation [32–34].This combination of
CS with AZA remained the cornerstone of IS for organ
transplantation until the introduction of Csa in the early
1980’s. However, CS continue to be used as ﬁrst line therapy
for the treatment of ACR and in patients transplanted
for auto immune diseases, often used as an adjunct in
maintenance with an agent such as CNI to prevent rejection.
6.2. Mechanism of Action. CS act primarily on T cell
activation by inhibiting the production of T cell cytokines
such as IL-2, IL-6, and interferon-gamma which are required
to enhance the response of lymphocytes and macrophages
to allograft antigens. They also suppress antibody and
complement binding and stimulate the migration of T cells
from the intravascular compartment to lymphoid tissue.
Table 2: Side eﬀects of corticosteroids.
Cardiovascular Sodium and ﬂuid retention,
hypertension
Gastroenterological Pancreatitis with high dose
steroids, peptic ulcer
Neurologic Psychosis, altered mood states,
headaches, pseudotumor
Opthalmic
Posterior subcapsular cataracts,
increased intraocular pressure,
glaucoma, exopthalmos
Musculoskeletal
Osteoporosis, vertebral and
femoral fractures, aseptic necrosis
of femoral head. Myopathy, muscle
weakness
Endocrine
Diabetes mellitus/glucose
intolerance, Cushingoid facies,
hyperlipidemia, growth
retardation, menstrual
irregularities, suppression of
pituitary-adrenal axis
Skin Acne, increased bruising, impaired
wound healing
Infectious Increased risk of infections,
including fungal
Table 3: Equivalent doses of steroids.
Glucocorticoid Dose (milligrams)
Hydrocortisone 20
Deﬂazacort 6
Prednisolone 5
Prednisone 5
Methylprednisolone 4
Triamcinolone 4
Dexamethasone 0.75
6.3. Side Eﬀects. A variety of side eﬀects have been reported
with corticosteroids (Table 2). Osteoporosis is a common
complication with an incidence greatest in the ﬁrst six
months post-LT and patients maintained on more than ten
milligramsperkilogramperdayshouldberegularlyscreened
and where appropriate, oﬀered treatment.
6.4. Drug Interactions. Most drug interactions with corti-
costeroids are of little clinical signiﬁcance. Antacids may
reduce absorption of deﬂazacort (Table 3). Csa increases the
plasma concentration of prednisolone while high doses of
methylprednisolone increase plasma concentrations of Csa.
6.5. Clinical Use in Liver Transplantation. Unfortunately,
acute and chronic dosing of corticosteroids are associated
with numerous side eﬀects which had led to several attempts
to minimize or eliminate their use during the early and
late post-LT period. Several attempts to reduce or eliminate
CS in corticosteroid use have been undertaken but this
requires great care as rapid steroid taper may be associated6 Journal of Transplantation
with an increased incidence of rejection or ﬂare of an
underlying disease. Although the use of CS varies between
LT programs, they remain an important component of our
pharmacological armamentarium although their use as an
adjunct in maintenance therapy will be limited to a few cases
due to the rapid development of newer and more potent
agents which lack their morbidity.
InpatientstransplantedforHCV,steroidsweretradition-
ally withdrawn rapidly (less than three months) and steroid
boluses avoided if possible. The concern had been that as
the HCV virus had a steroid-responsive element, the use of
steroids was associated with enhanced viral replication, and,
thus more aggressive viral recurrence. Although this holds
true for patients with recurrent HCV who receive steroid
boluses, particularly when rejection cannot be unequivocally
diﬀerentiated from recurrent viral hepatitis, this observation
could not be extrapolated to maintenance steroid use. A
provocative retrospective study ﬁrst raised concerns about
rapid taper of maintenance steroids in this patient popula-
tion by reporting more severe recurrent HCV in this sub-
groupofpatients[35].Theinvestigatorsanalyzedtherecords
of all the patients transplanted for HCV between 1991 and
1997 and followed 80 consecutive patients who survived
more than one month after LT for a median of 45 months. 38
patients (47.5%) of patients were diagnosed with recurrent
HCV, 22 had severe recurrent disease, and decompensated
cirrhosis occurred in six patients (7.5%). The only factor
associated with both recurrence and severity of HCV was
the method of CS tapering-in patients receiving a higher
daily prednisone dose 12 months after transplantation, the
proportion of recurrent hepatitis C was 35.7% versus 66.6%
(P = .02; odds ratio (OR), 3.6; 95% CI: 1.25 to 10.36),
and among patients receiving a higher daily prednisone
dose, six months after transplantation, the proportion of
moderate/severe HCV was 40% versus 89% (P = .03; OR:
0.08, 95% CI: 0.008 to 0.84). Prednisone dose at month
six was signiﬁcantly associated with disease-free survival of
the liver graft. The same investigators recently reported the
results of their prospective randomized study comparing
rapid versus slow taper in patients transplanted for HCV
and conﬁrmed that rapid tapering was associated with more
severe recurrent disease [36]. They recommended that CS
should be tapered slowly in these patients using a dose of
2.5–5mgforuptotwoyearsalthoughitremainsunclearhow
long such patients should be treated with steroids [37].
7.Rapamycin
7.1. Background. Sirolimus (Rapamycin, Wyeth-Ayerst) is
a macrolide compound with a molecular weight of 914.2
derived from the actinomycete Streptomyces hygroscopicus. It
was discovered in soil samples brought from Easter Island
(Rapa Nui) by the Canadian Medical Research Expedition
between December 1964 and February 1965. Sirolimus has
a long history dating from the 1970s at the same time when
Csa was discovered and was considered to have novel anti
fungal properties. However, it was not further developed
as several side eﬀe c t sw e r en o t e ds u c ha sl y m p h o i dt i s s u e
regression and immunosuppressive eﬀects in rat models of
autoimmune diseases. This led to studies on the eﬃcacy of
the compound in mouse and rat organ allograft models in
the mid 1980’s, particularly after structural homology was
noted between sirolimus and tacrolimus. Rapamycin was
launched for clinical use in organ transplantation in 1999.
7.2. Mechanism of Action. Sirolimus is a potent immuno-
suppressant which exerts its immunosuppressive eﬀects by
inhibiting IL-2 and IL-15 driven proliferation of hematopoi-
etic (B and T cells) and non hematopoietic cells such as
vascular smooth muscle cells [38]. Sirolimus also decreases
antibody production by B cells. This occurs at relatively
low blood levels in vivo. In animal models, sirolimus acts
synergisticallywithCsasuggestingadiﬀerenceinmechanism
of action between sirolimus and calcineurin inhibitors.
Despite the structural homology between sirolimus and
tacrolimus with both drugs binding to the same intracellular
immunophilin, FK506 binding protein, a 12-kDa binding
protein (FK Binding protein-12) in T cells, the two drugs
act synergistically rather than competitively and also diﬀer
in their mechanism of action. Csa and tacrolimus (which
inhibit the phosphatase calcineurin after binding to heir
respective immunophilins FKBP and cyclophilin, respec-
tively) inhibit early events in T cell activation particularly
the expression of IL-2 in the G0-G1 stage of the cell
cycle. Sirolimus which also binds to the FKBP family,
particularly FKBP-12, does not bind to calcineurin but
instead binds to target molecules with kinase activity called
MTOR (mammalian targets of rapamycin), also known as
FRAP and RAFT. MTOR plays a key role in the signal
transduction pathways downstream to many growth fac-
tor receptors (including the IL-2 receptor) and the PI3
kinase/AKT/protein kinase B pathway. TOR and possibly the
phosphatase PP2A control the phosphorylation of proteins
that regulate the translation of mRNA’s encoding regulators
of the cell cycle such as translation inhibitor 4E-BP1,
eukaryotic translation initiator protein 4G1, p70S6kinase,
(which in turn phosphorylates 40S ribosomal protein S6)
and cyclin-dependent kinases [39]. This may be mediated
directly or indirectly as TOR acts partly by regulating PP2A.
The immunosuppressive activity of sirolimus activity is
primarily related to blockade of IL-2 and IL-15 induction
of B and T cell proliferation via inhibition of p70S6
kinase through high aﬃnity binding to FKBP and prevents
progression of the cell cycle from the G1 to S phase. In
other words, rapamycin allows T cell activation but prevents
these cells from proliferating in response to IL-2.This is
particularly relevant in lymphoid cell as demonstrated by the
observation lymphocyte proliferation is arrested even when
rapamycin is administered twelve hours after initiation of
stimulation. An interesting eﬀect of sirolimus is its potential
anti-tumor eﬀect, presumably by a similar mechanism by
which it aﬀects immune cells but in addition there is
evidence sirolimus may inhibit angiogenesis. This may occur
via inhibition of transcription factors such as hypoxia-
inducible factor 1a (H-IF 1a) which results in a decrease
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endothelial growth factor. It may be possible in the future to
predict which tumors may be sensitive to mTOR inhibitors
by examining the status of the PI3K/AKT pathway of these
tumors. However, there is currently insuﬃcient clinical
data to support sirolimus use for the prevention and/or
treatment of patients with hepato-biliary carcinoma pre or
post transplant [40].
Sirolimus has also demonstrated potent anti fungal and
anti proliferative properties, independent of immunosuprre-
siveactivity.Zhuetal.investigatedtheeﬀectsofsirolimusina
carbon tetrachloride model of hepatic ﬁbrosis in rats and on
hepatic stellate proliferation in vitro [41]. The investigators
noted that sirolimus inhibited extracellular matrix deposi-
tion in a rat model of ﬁbrogenesis as determined by histolog-
ical analysis, collagen content, messenger RNA levels of pro-
collagen, and transforming growth factor beta-1 and tissue
transglutaminase activity. In addition, sirolimus decreased
platelet growth factor-induced proliferation of hepatic stel-
late cells, supporting the hypothesis sirolimus may inhibit
hepatic ﬁbrosis and thus prevent or delay the development
of cirrhosis. Others have reported that enhanced immuosup-
pression by sirolimus may actually enhance viral replication
but adequately controlled trials evaluating these outcomes
have yet to be performed and there is currently insuﬃcient
evidence to support or refute either concern. Sirolimus was
approved by the U.S. Food and Drug administration only for
use in renal transplantation in 1999.
7.3. Pharmacokinetics and Pharmacodynamics. Am a j o rl i m -
itation with sirolimus was the development of a proper
oral formulation with acceptable stability, bioavailability and
predictability in absorption characteristics. The compound
is very lipophilic and hence poorly soluble in water but in
oily solution or microemulsion is readily absorbed after oral
administration. Sirolimus is also freely soluble in acetone,
acetonitrile,benzylalcohol,andchloroform.Oralabsorption
is rapid with a bioavailabilty of 14% with oral solution
and 18% with tablets. Absorption is reduced in African
Americans and in the presence of a high- fat diet. Levy
et al. studied the route of administration, eﬀect of bile
duct diversion, and time after liver transplantation on 26
liver transplant recipients and reported that none of these
factors inﬂuenced sirolimus absorption [42]. However, the
long half-life of sirolimus and narrow therapeutic window
necessitates regular therapeutic drug monitoring (These
concerns led to the development of Everolimus, a sirolimus
derivative with improved physicochemical properties cur-
rently undergoing trials in organ transplant recipients). The
50% inhibitory concentration for sirolimus inhibition of
FK506bindingtoFK506binding protein12isapproximately
0.4–0.9 nano moles per liter (nmol/L).
The volume of distribution of sirolimus is 12 ± 7.52
liters per kilogram of body weight. Extensive uptake occurs
in blood cells with up to 95% of uptake occurring in
erythrocytes. Sirolimus is extensively bound to plasma
proteins (92%), particularly albumin, alpha-one acid gly-
coprotein, and lipoproteins. Sirolimus undergoes exten-
sive hepatic metabolism by the P450 3A4 cythochrome
enzymes and produces the metabolites hydroxysirolimus,
demethylsirolimus and hydroxydemethysirolimus. Sirolimus
bioavailability and clearance are dependent on intestinal
and hepatic metabolism by cytochrome P-450 (CYP) 3A4
enzymes. Elimination occurs in 57 to 63 hours but may be
signiﬁcantly increased up to 72 hours in males although no
dosage adjustment is required. Steady state is usually reached
ﬁve to seven days after dose adjustment. The majority
(91%) of the metabolites of sirolimus are eliminated in
feces via the multidrug eﬄux P-glycoprotein pump into the
gastrointestinal lumen with only a minor amount (2.2%)
recovered from urine.
Peak blood concentraion in renal transplant recipients
was 12.2 ± 6.2 and 37.4 ± 21 nanograms per milliliter
(ng/mL) in renal transplant patients administered twomg
and ﬁve milligrams, respectively, of sirolimus in combi-
nation with Csa and CS. Diﬀerences in sensitivity and
speciﬁcity exist between diﬀerent methods of detection (e.g.,
immunoassays versus high performance liquid chromatog-
raphy) with chromatographic methods can yield values
20% lower than whole blood immunoassay levels. Using
immunoassays, whole blood concentration averages nine
ng/mL in patients who received twomg of sirolimus per
day and 17ng/mL in patients who received ﬁvemg of
sirolimus per day [43]. Sirolimus pharmacokinetics can
also be altered during drug coadministration. For example,
when sirolimus is administered concomitantly with the
microemulsion formulation of Csa rather than administered
separately four hours apart, sirolimus trough levels increase.
Furthermore, diltiazem and ketoconazole increase sirolimus
peak concentration while rifampin decreases it. Therapeutic
drug monitoring is therefore required to achieve the best
clinical outcome in selected cases. The immunosuppressant
eﬀect of sirolimus can last for up to six months after
discontinuation in some animal studies.
7.4. Side Eﬀects. T h em o s tc o m m o ns i d ee ﬀects are dose-
related hyperlipidemia and cytopenias such as thrombo-
cytopenia, anemia and leucopenia. Dyslipedemia has been
reported in up to 80% of renal transplant recipients
on sirolimus with mean cholesterol levels of 240mg/dL
although the prevalence in liver transplant recipients is
reported to be approximately 44% [44]. Trotter et al.
reported that hyperlipidemia and hypercholesterolemia were
more common and severe in patients on sirolimus-Csa
compared to sirolimus-tacrolimus combination therapy
[45]. However, it remains unclear if dyslipidemia-associated
sirolimus translates into an increased risk of atherosclerosis,
a multifaceted, multifactorial complex disease process inﬂu-
enced not only by eleveated levels of serum lipids but under-
lying inﬂammation, ﬁbrogenesis and cellular proliferation,
processes which may be inhibited by sirolimus.
Unlike CNI’s, nephrotoxicty is uncommon although
proteinurialeadingtonephroticsyndromehasbeenreported
and in renal transplant recipients, sirolimus has been
associated with a higher incidence of nephrotoxicity when
used with Csa but not tacrolimus [46]. Animal studies
have suggested sirolimus enhances the nephrotoxic eﬀects8 Journal of Transplantation
of Csa by increasing renal partitioning of this drug into
the renal tubular cell [47]. Arthalgias and aphthous ulcers
have also been reported with the use of sirolimus. An
uncommon but potentially life-threatening complication
of sirolimus is interstitial pneumonia which necessitates
immediate cessation and steroids [48].
Liver tests abnormalities are occasionally seen and occur
a mean of 21 days after initiation of sirolimus [49]. A
variety of histological changes have been described including
sinusoidal congestion and eosinophilia, all of which reversed
within one month of drug discontinuation. Sirolimus has
received a black box warning in liver transplantation due to
an increased incidence in hepatic artery thrombosis (HAT)
in the ﬁrst post operative month. Wound dehiscence has
also been reported in a variety of transplant recipients on
sirolimus which has led to substitution of rapamycin for
an alternative immunosuppressant in patients undergoing
elective surgery and avoidance in the ﬁrst month of trans-
plantation due to the twin risks of dehiscence and HAT [50].
Despite a single center study in liver transplant recipients
showed no evidence of an increased risk of HAT or wound
dehiscence with sirolimus, most if not all liver transplant
programs avoid sirolimus use in the ﬁrst post operative
month [51, 52].
7.5. Drug Interactions. As sirolimus is metabolized by the
P450-3A4 microsomal system, drugs which inhibit or induce
this system can signiﬁcantly aﬀect sirolimus metabolism.
Common examples of drugs which inhibit sirolimus
metabolism leading to potentially toxic levels include ery-
thromycin, ﬂuconazole, and protease inhibitors. Phenytoin
has been reported to activate sirolimus metabolism leading
to sub therapeutic levels [53].
7.6. Clinical Use in Liver Transplantation. Experience with
sirolimus in LT is limited in contrast to its use in renal
transplantation. It has been used in conjunction with low
dose calcineurin inhibitors shortly after transplantation or
as monotherapy months or years after transplantation in an
attempt to prevent or mitigate calcineurin nephrotoxicity.
Watson et al. were the ﬁrst to report their experience
with sirolimus in 15 liver transplant recipients in 1999
[54]. Three diﬀerent sirolimus-based protocols were used:
prednisolone, microemulsion Csa and sirolimus; Csa and
sirolimus and sirolimus monotherapy—all patients were on
sirolimus monotherapy by three months post-transplant
with a follow-up between 117–806 days. Rejection was more
common on monotherapy than double therapy but absent
on triple therapy. Sirolimus was generally well tolerated
with only three patients discontinuing sirolimus: one each
for hyperlipidemia, pneumocystis pneumonia, and taste
intolerance.Theauthorsconcludedsirolimuscombinedwith
Csa provided potent immunosuppression of liver allografts
with sirolimus monotherapy adequate and well tolerated
for maintenance therapy. This seminal work led to an
important study by McAlister et al. who reported their
experience with sirolimus in combination with tacrolimus in
32solidorganrecipientsofwhom23hadundergoneLT[55].
Only one patient (3%) experienced ACR who upon further
investigation was discovered to have discontinued sirolimus.
Pridohletal.reportedtheirexperiencewithin22patients
who received sirolimus, tacrolimus and CS [56] Patient and
graft survival at one year were 91% and 78%, respectively.
Subsequent studies with larger numbers of patients, albeit
non randomized, have been encouraging with excellent
patient and survival rates in concert with low rates of acute
rejection or steroid-resistant rejection [57, 58]. Trotter et
al. compared their experience in 39 patients with Csa or
tacrolimus with sirolimus and rapid steroid taper over three
days with historical controls [59]. After a mean follow-up of
124days,theyobserveda30%reductioninrateofACR(48%
versus 70%; P<. 05) and 65% reduction in steroid-resistant
rejection (8% versus 37%; P<. 05).
Several , single-center, non randomized studies have
reported improved renal function in liver transplant recip-
ients on CNI’s inhibitors switched to either low dose CNI’s
and sirolimus or sirolimus monotherapy. Fairbanks et al.
converted 21 patients on CNI’s to sirolimus monotherpay
(n = 18) and sirolimus with low dose steroids (n = 3)
and followed patients for a mean of 66.8 ± 38.9w e e k s
after conversion [60]. Renal function improved in 71% of
patients(15of21patients)andmedianestimatedglomerular
ﬁltration rate (GFR) improved by 27% (P = .01). In a
retrospective study of 38 pediatric LT recipients, Casas-
Melley et al. reported that patients with renal impairment
(11 patients) showed improvement in serum creatinine
levels from a mean baseline of 1.3 to 0.8 milligrams
per decilitre (mg/dL) with calculated creatinine clearance
(Schwartz formula) improving from 63.7 to 84.8milliliters
per minute (mL/min) (P = .03) [61] They also reported that
patients started on sirolimus for rejection showed signiﬁcant
improvement in hepatocellular enzymes despite a reduction
in the tacrolimus level from 12.2 to 7.5ng/mL. However, this
observation was limited by the absence of serial liver biopsies
following initiation of sirolimus
Recent and more elegantly-designed studies have ques-
tioned the renal-toxic sparing eﬀects of sirolimus. In a ran-
domizedcontrolledtrialofconventionalISwithCNI’sversus
sirolimus-based IS on 30 patients (greater than six months
post-liver transplantation), therewas amodest improvement
in change in GFR following sirolimus conversion at three
and twelve months [62]. Although the diﬀerence in absolute
GFR between the two study arms was signiﬁcant at three
months, this did not hold true at 12 months. These ﬁndings
were supported by Shenoy et al. who randomized 40
liver transplant recipients with renal dysfunction (24 hour
creatinine clearance 40–80 mL/min) to maintenance therapy
with CNI’s or sirolimus [63]. They noted a signiﬁcant
improvement in creatinine clearance in the sirolimus arm
at three months but at 12 month follow -up, there was no
statistical diﬀerence between the two drugs. Dubay et al.
reported the impact of sirolimus on renal dysfunction in
an elegantly designed case-control study of LT recipients
with renal dysfunction [64]. 57 patients were treated with
sirolimus after more than 90 days post operatively and for at
least 90 days. The control group consisted of 57 patients on
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The investigators noted that patients exposed to CNI’s for
more than ﬁve years or those with a creatinine clearance
less than 30mL/min when converted to sirolimus actually
faredworsethanpatientsmaintainedonlowdoseCNI’s.Fur-
thermore,progressiontorenalreplacementtherapy,episodes
of rejection and death were similar between the two arms
although side eﬀects were more common in the sirolimus
arm. The authors concluded that there was no advantage to
sirolimus conversion in liver transplant recipients with CNI-
related nephrotoxicity. These ﬁndings suggest the renal-toxic
preventing eﬀects of sirolimus are more likely to be achieved
whentreatmentisinitiatedintheearlypost-LTperiodbefore
CNI-nephrotoxicity has developed.
8.PurineSynthesisInhibitors
This section will only review mycophenolic acid as older
purine antagonists such as azathioprine and cyclophos-
phamide are no longer used in LT.
9. Mycophenolate Mofetil
9.1. Background. Mycophenolate mofetil (MMF) is a mor-
pholinoethyl ester of mycophenolate which is produced
by several species of the fungus Penicillium and was ﬁrst
discovered in 1893. MMF was developed by Allison and
colleagues and is hydrolysed to its active form, mycophe-
nolic acid (MPA) [65]. MMF is available in two forms:
MMF (CellCept, Roche) and enteric-coated mycophenolate
sodium (Myfortic, Novartis). Although MMF is rapidly
absorbed in the stomach before it is converted to MPA,
the enteric-coated preparation releases MPA in the small
intestine via a pH-dependent mechanism [66]. Inter-
estingly, side eﬀects with the enteric form persist and
appear to occur independently of gastrointestinal absorption
as conﬁrmed in randomized, double-blind studies [67,
68].
9.2. Mechanism of Action. In 1969, MMF was discovered to
block de novo purine nucleotide synthesis by inhibiting type
2 inosine monophosphate dehydrogenase (IMPDH) and
the production of guanosine nucleotides such as guanosine
monophosphate (GMP) [69]. MMF inhibits type 2 IMPDH
nearly ﬁve times more potently than type 1 IMPDH which
predominates in resting cells. The mechanism of type two
IMPDHinhibitionisbelievedtoinvolvethebindingofMMF
to the nicotinamide site which prevents the conversion of
IMP to GMP [70]. In vitro studies have shown MPA inhibits
antibody formation, does not aﬀect production of cytokines
implicated in allograft rejection, inhibits transfer of fucose
and mannose to glycoproteins including adhesion molecule
and inhibits smooth muscle cell proliferation.
Cells depleted of GMP are unable to synthesize guanine
triphosphate(GTP)anddeoxyguaninetriphosphate(dGTP)
and therefore cannot replicate unless they are able to
maintain GMP levels through the purine salvage pathway. B
andTlymphocyteslackakeyenzymeofthissalvagepathway,
hypoxathine guanine phosphoribosyl transferase, and are
therefore unable to replicate in the presence of MMF as they
cannot bypass this MPA-induced block with cells staying
in the S phase of the cell cycle [71]. MMF therefore has a
powerful cytostatic eﬀect on lymphocytes by inhibiting both
mitogen- and alloantigen-induced stimulation. The eﬀects
of MMF can be reversed by guanosine and deoxyguanosine.
MMF also reduces recruitment of leucocytes to inﬂamma-
tory sites.
9.3. Pharmacokinetics and Pharmacodynamics. MMF is
rapidly absorbed after oral administration and hydrolyzed to
MPA. Bioavailability is between 90–94% but food decreases
MPAconcentrationssoMMFshouldbeadministeredatleast
one hour before or two hours after meals.
Mean volume of distribution is 3.6l L/kg (intravenous
preparation) and 4 L/kg (oral). Protein binding is 97%
(MPA)and82%forMPAG,aninactivemetabolite.FreeMPA
is the pharmacologically active fraction.
MMF is rapidly and completely hydrolysed to MPA
which is converted to inactive MPA glucuronide by hep-
atic glucuronyl transferase. Since genetic variations of this
enzyme exist, the eﬀectiveness of MPA and level of glu-
curonidation may vary. The liver is assumed to be the
primary site of MPAG production but it remains unclear if
extra-hepatic production occurs. MPAG undergoes entero-
hepatic recycling and is converted to MPA.
MMF is excreted in MPAG mostly in the urine (93%)
and feces (6%). Following oral administration, half-life and
plasma clearance of MPA are 17.9 hours and 193mL/min
which is reduced slightly to 16.6 hours and 177mL/min,
respectively following intravenous administration. Liver dis-
ease impairs MPA conjugation which prolongs MPA half-
life. Interestingly, ﬂuctuations in albumin levels which are
common in liver transplant recipients can lead to ﬂuctua-
tions in MMF pharmacokinetics, changes which are not seen
commonly in renal transplant recipients [72].
9.4. Side Eﬀects. The most common side eﬀects are gas-
trointestinal (anorexia, abdominal pain, gastritis, diarrhea in
up to 30%) and hematological (neutropenia in up to 3%)
which are usually dose-related. This requires dose reduction
or cessation between 24–57% of patients but if the white
cell count does not rise after dose reduction, MMF should
be stopped. Although MMF is usually dosed at 1g twice
a day, patients may tolerate the drug better if started at
500mg twice a day or four times a day. MMF does not cause
nephrotoxicity or neurotoxicity.
9.5. Drug Interactions. Drugs which may increase plasma
concentrations of MPA include acyclovir, ganciclovir,
probenecid, salicyaltes and sirolimus. Drugs which may
reduce MPA levels include but are not limited to antacids
containing aluminium or magnesium, cholestyramine,
iron, metronidazole, norﬂoxacin, and rifampin. MPA also
decreases protein binding to phenytoin and theophylline
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potentiates the anti-herpetic activities of acyclovir and gan-
ciclovir and should not be given with other anti-metabolites
such as AZA.
9.6. Clinical Use in Liver Transplantation. Although MMF
acts similarly to AZA, it is a more eﬀective immunosup-
pressant with fewer side eﬀects rendering AZA use virtually
obsolete in liver transplantation. As MMF does not cause
nephrotoxicity or neurotoxicity, it has been widely use as a
CNI-sparing agent and has been used in LT since the early
1990’s [73–75]. When used in combination with tacrolimus
and steroids versus tacrolimus and steroids in a randomized
controlled trial, Jain et al. reported that patients in the MMF
group experienced fewer episodes of acute cellular rejection,
similar patient and graft survival and improved renal
function and lesser amount of maintenance steroids [76].
However, the favorable eﬀect of MMF was lost when MMF
was stopped which occurred in 37% of patients secondary
to infections complications and bone marrow depression.
MMF has also been evaluated for the treatment of refractory
rejection in liver transplant recipients. In one retrospective
study of 47 patients, MMF was added to Csa or tacrolimus
with steroid-resistant rejection, of whom 12 did not respond
to OKT3 [77]. Liver function tests normalized in 81% of
patients (follow-up biopsies were not reported) although
gastrointestinal and hematological side eﬀects occurred in
31.4%. Serum creatinine decreased signiﬁcantly within two
weeks of MMF with reduced CNI dosing and creatinine
clearance increased within three months in 77.9% of patients
treated with MMF and reduced dose CNI. Akamatsu et
al. reported that 81% of patients with steroid-resistant
rejection after living donor liver transplantation responded
to the addition on MMF and only 19% of patients required
OKT3 [78]. Although gastrointestinal and hematological
side eﬀects were common, there was no increased in the
incidence of infections with the authors concluding MMF
had a valuable role in the treatment of steroid-resistant
rejection before the initiation of monoclonal antibodies.
Data on the impact of azathioprine and MMF on HCV
recurrence has been at odds. A well-designed, randomized,
prospective study of 106 patients comparing tacrolimus plus
steroids vs tacrolimus plus steroids plus MMF showed no
eﬀectofMMFonpatientorgraftsurvivalorHCVrecurrence
[79]. However, subsequent studies, albeit smaller in size
and nonrandomized, have reported worsening HCV RNA
viremia with either AZA substitution for MMF or when AZA
is compared with MMF [80]. Wiesner et al. also recently
reported that MMF was an important factor in improved
outcomes in patients on tacrolimus-based immunosuppres-
sion after a multiple regression analysis of 11670 patients
reported to the SRTR [81]. The wide spectrum of reported
results is diﬃcult to interpret but nonetheless a common
factorinalltheearlier-describedstudiesisnotwhetherMMF
is superior to AZA but rather the overall intensity of IS
may have more of an impact on HCV recurrence than the
independent action of either drug.
As MMF is not nephrotoxic, it has a role similar to
rapamycin as a calcineurin-sparing agent in patients with
renal dysfunction. However, it has no role as monotherapy in
liver transplantation due to an unacceptably high incidence
of ACR, severe chronic rejection requiring retransplantation
and severe steroid-resistant rejection [82, 83].
10. Antilymphocytic Antibody Therapy
The original concept of lymphoid depletion in LT was
described by Starzl et al. [84]. Subsequent studies demon-
strated that antibody therapy to speciﬁc antigens on B and
T cells will deplete these cell populations although their use
has historically been limited to the peri operative period
(in an attempt to reduce CNI-mediated nephrotoxicity or
acute cellular rejection) and for the treatment of steroid-
resistant rejection. Monoclonal and polyclonal antbodies are
often classiﬁed as “depleting” agents not only for their eﬀect
on B and T cells but due to the intravascular release of
cytokines from lymphocytes. This can lead to hypotension,
fever, brochospasm and tachycardia which can often be
treated by pretreatment with steroids, antihistamines, and
acetaminophen.
11. Monoclonal Anti-T- Cell
Receptor Antibodies
11.1. Background/Discovery. In 1979, Kung et al. were the
ﬁrst to produce mouse monoclonal antibodies against T cell
surface receptor antigens using hybridoma technology [85].
11.2. Mechanism of Action. Of the three monoclonal anti-
bodies discovered by Kung et al., one antibody called
muromonab-CD3 (OKT3) had deﬁned speciﬁcity to the
CD3 receptor of the T cell, reacting with more that 95%
of peripheral mature T cells without aﬀecting immature
thymocytes. Binding of OKT3 to the CD3 complex causes
internalization of the CD3 receptor and loss of CD3
positive cells from the periphery which can be monitored
by simple laboratory tests-successful OKT3 treatment is
associated with a prompt decline in CD3 positive T cells
from approximately 60% to less than 5% [86]. Monitoring
of the absolute neutrophil count is occasionally used and
if levels less than 500 cells per milliliter are not reached,
some authorities recommend repeating the OKT3 dose in an
attempt to overwhelm the developing antibodies.
11.3. Pharmcokinetics and Pharmocodynamics. OKT3 is
administered intravenously as a bolus injection and reaches
steady-state trough levels by three days. Time to onset
of action is within minutes and duration of activity is
approximately one week.
11.4. Side Eﬀects. Severe side eﬀects are related to the release
of proinﬂammatory cytokines in response to the ﬁrst few
doses of OKT3. They include fever, hypotension, headache
from aseptic meningitis, dyspnea from ﬂash pulmonary
edema, and gastrointestinal complaints such as nausea,
diarrhea, and vomiting. These symptoms may be prevented
by pretreatment with antihistamines, acetaminophen andJournal of Transplantation 11
steroids (steroids only used before ﬁrst dose of OKT3).Onset
is usually within one hour and symptoms often resolve
within four to six hours.
Post transplant lymphoproliferative disease (PTLD) may
develop more frequently in patients treated with OKT3 and
concern has been raised that this complication may occur
commonly in patients transplanted for HCV [87]. Two large
studies showed an incidence of PTLD of approximately 3%
in LT recipients exposed to OKT3-although one of these
studies showed a strong association between PTLD and
OKT3 exposure, this was not reproducible in the other
[88, 89].
11.5. Clinical Use. OKT3 was ﬁrst used in LT in 1987
for treatment of ACR in a multicenter randomized trial
[90]. 28 patients who failed to respond to two doses of
methylprednisolone boluses were randomized to continue
steroid therapy versus switched to OKT3. Three of 13
patients assigned to the steroid group responded promptly
and maintained normal liver function for a mean of 9.5
months.OKT3rescuewasrequiredintenpatientswhofailed
to improve despite receiving up to 6 grams of methylpred-
nisolone (mean: 3.3 grams per patient). One patient died
of sepsis and hepatic failure. Rejection was reversed in nine
OKT3-rescue patients, seven of whom are well 1–17 months
later. In the OKT3 group, improved allograft function was
observed within 72 hours in 11 of 15 patients. Two patients
with inadequate response were successfully rescued with
steroids; one patient underwent retransplantation; and one
patient developed a biliary ﬁstula that eventually resulted in
sepsis and death. Overall, 82% of patients were alive with the
originalallograft1–17(mean7.8)monthsaftertreatmentfor
acute rejection with one patient alive 14 months following
retransplantation. Eighteen (78%) of the survivors required
OKT3 as initial [11] or rescue (seven) therapy, whereas
only ﬁve were successfully managed with steroids. This early
trial demonstrated that OKT3 was superior to steroids for
reversing liver allograft rejection and may reduce the need
for retransplantation even in recipients selected on the basis
of having failed initial steroid therapy.
A subsequent multicenter randomized trial was per-
formed to compare the incidence of ACR and renal failure
between two immunosuppressive protocols [91]. 46 patients
were randomized to a 14-day treatment with OKT3 in
association with CS and AZA, Csa being progressively intro-
duced on day 11 post-LT. Fifty patients were randomized
to a standard protocol of Csa with CS and AZA. Minimum
follow-up was one year and graft and patient survivals were
updated for the purpose of the study. The cumulative one-
year incidence of ACR was greater in the Csa group (75%)
than in the OKT3 group (67%), especially when patients
who did not receive full-course treatment with OKT3 were
excluded (59%). Renal function was better preserved during
the ﬁrst two postoperative weeks in the OKT3 group than
in the control group but plasma creatinine levels were com-
parable in both groups thereafter. Surprisingly, incidence of
severe infections was lower in the OKT3 group (13.6%) than
in the Csa group (32%) although the four year incidences
of patient and graft survival in the OKT3 group (69% and
61%, resp.) were not diﬀerent from those in the Csa group
(62%versus54%,resp.).ThisprospectivetrialshowedOKT3
immunoprophylaxis may be a reasonable alternative to Csa
immunoprophylaxis in unselected recipients of a ﬁrst liver
graft.
In addition to the cytokine-mediated side eﬀects of
O K T 3 ,as e r i o u ss i d ee ﬀect includes rapid acceleration of
HCV replication leading to severe recurrent disease. In a
retrospective study from 1997, Rosen analyzed outcomes
for two groups of patients with steroid resistant rejection,
of whom one group received OKT3 (n = 19) and the
other was OKT3 na¨ ıve (n = 33) [92]. Both groups were
matched for age, gender, immunosuppression, and HCV
status. The investigators observed that not only did HCV
recur earlier in the OKT3-treated group but disease severity
was signiﬁcantly greater with a higher proportion of patients
developing cirrhosis. This landmark study has signiﬁcantly
altered the use of OKT3 in liver transplant recipients with
recurrent HCV—at present, polyclonal antibodies are used
as an alternative to monoclonal antibodies if the diagnosis
of acute rejection is unequivocal and has not responded to
other standard interventions.
12. Polyclonal Antibodies
12.1. Background. Although anti lymphocyte antibodies
have been in clinical use for the last 2 decades, their use
in liver transplantation, particularly with polyclonal anti
bodies, continues to evolve. Polyclonal antilymphocyte anti-
body preparations are heterologous preparations. Animals
(including rabbits and horses) are immunized with human
T cells and thymocytes, and antisera are collected. A puriﬁed
gamma globulin fraction (antithymocyte globulin) is used
to reduce the likelihood of serum sickness. The US Food
and Drug Administration approved antithymocyte globulin
preparations are ATGAM of equine origin (Pﬁzer, New York)
and thymoglobulin of rabbit origin (Genzyme, Boston).
The limitations of the antithymocyte globulin preparations
are related to variability in potency; reactivity to formed
blood elements leading to leukopenia, thrombocytopenia, or
anemia; and serum sickness. Only antithymocyte globulin of
rabbit origin (ATG) will be discussed as the use of ATGAM
in the United States for LT is not common.
12.2. Mechanism of Action. ATG is a rabbit-derived poly-
clonal antibody directed against human thymocytes which
leads to depletion of peripheral lymphocytes and peripheral
lymphopenia. Characterization of the antigen speciﬁcity
of these preparations suggests that multiple cell surface
molecules are recognized by the polyclonal antibody prepa-
rations, and the varying speciﬁcities may account for the
variations in their clinical eﬃcacy [93]. The antibodies are
directed not only to multiple T cell antigens such as CD2,
CD3, CD4, CD8, CD28, and the T cell receptor but also to
antigens on B cells (CD20 and CD40), HLA classes 1and
2, macrophages and natural killer (NK) cells [94]. These12 Journal of Transplantation
polyclonalantibodiesoperateviaantibody-mediatedopsoni-
sation and cytolysis, cell depletion by apoptosis, complement
mediated cell lysis and internalization of the cell surface
receptors.Thebiologicaleﬀectofthedepletingantibodiesare
profound and can last longer than heterologous antibodies
[95].
There is also evidence from in vitro in and vivo studies
that ATG thereapy results in expansion of regulatory T cells
[96–98]. This may allow any remaining lymphocytes and/or
new lymphocytes to engage the transplanted liver and either
recognize the donor organ as self or develop an adaptive
immune response which prevents hepatic allograft rejection.
Clinical studies are underway to test this hypothesis and to
determine whether ATG may promote allograft tolerance.
12.3. Pharmacokinetics and Pharmacodynamics. ATG has a
half life of approximately three days.
12.4. Side Eﬀects. ATG is tolerated better than OKT3
although premedication with anti histamines and
acetaminophen is commonly performed Leucopenia
and thrombocytopenia are common side eﬀects which are
dose-related although serum sickness has also been reported.
12.5. Clinical Use. ATG has been used as an induction agent
andsteroid-sparingagentinLTandalsousedtotreatsteroid-
resistant rejection. An early randomized controlled trial by
Eason et al. compared outcomes of induction with ATG
(n = 36) versus CS (n = 35) followed by maintenance
IS with tacrolimus and MMF, with or without steroids, in
both groups [99]. Overall survival and graft rates were 91%
and 89% for both groups. 20.5% of patients treated with
ATG had biopsy-proven rejection successfully treated with
increasing tacrolimus doses. 32% of patients administered
steroid induction had biopsy-proven rejection of whom 64%
required additional steroids for treatment whereas 36% were
successfully treated by increasing tacrolimus doses. The inci-
dence of rejection was not statistically signiﬁcant although
there was a signiﬁcant diﬀerence in the incidence of steroid-
requiring rejection (P = .01). A further important ﬁnding
of this study was that the incidence of recurrent HCV was
50% in ATG patients versus 71% in steroid patients although
this was not statistically signiﬁcant. Overall incidence and
severity of infectious complications were slightly lower in
ATG patients due to a greater incidence of cytomegalovirus
(CMV) infection in the steroid patients. The ﬁndings from
this prospective randomized trial supported the use of ATG
as a reasonable alternative induction agent to steroid boluses.
The same investigators reported a two year follow -up of
patients from this study which also included 48 additional
patients [100]. This study, however, was complicated by new
modiﬁcations in the IS regimen. In patients who received
steroid induction, steroids were tapered over three months.
MMF was discontinued over three months in the ﬁrst 71
patients and overtwoweeks in the next cohort of 48 patients,
leaving tacrolimus monotherapy as the default immunosup-
pressantasearlyastwoweekspost-LT.Endpointsofthestudy
were survival, rejection, infectious complications, post-LT
diabetes, and recurrent HCV. One year patient survival was
85% in both groups while one year graft survival was 82%
in the ATG group and 80% in the steroid group (P = not
signiﬁcant). Although the incidence of rejection was not
signiﬁcantly diﬀerent, 50% of patients in the steroid group
required pulse steroids to reverse the rejection compared
with only one patient (1.6%) in the ATG group (P = .03).
The incidence of cytomegalovirus infection (P<. 05) and
post-LT diabetes was higher in the steroid group (P = .03)
with a trend toward decreased severity of hepatitis C virus in
the ATG group.
To evaluate the impact of ATG on recurrence of HCV,
Nair et al. randomized 64 patients to induction therapy with
steroids versus ATG followed by maintenance tacrolimus and
comparedliverfunctiontests,HCVRNAlevelsandhistology
at three-six months post-LT [101]. All patients received
antiviral therapy with interferon alpha 2b and ribavirin
in the absence of clear contraindications. There was no
statistically signiﬁcant diﬀerence between the two groups in
terms of inﬂammation at three months, peak ALT or HCV
RNA. The survival between the two groups of patients was
also similar suggesting that steroid-free liver transplantation
with ATG induction has no negative inﬂuence on HCV
recurrence after a short-term follow-up. These ﬁndings
were echoed by De Ruvo et al. following a retrospective
analysisaimedatdiscoveringanyrelationshipbetweenRATG
immunosuppression and the pattern of recurrence of HCV
[102]. The investigators compared outcomes between 22
HCV patients who received ATG induction plus tacrolimus
monotherapy with 30 HCV patients receiving transplants
within the same year who received conventional tacrolimus
plus CS. Patient survival and acute rejection rate did not dif-
fer between the two groups. Signiﬁcantly lower dosages and
levelsoftacrolimuswerepossiblewithATGandaprogressive
weaning of tacrolimus monotherapy was accomplished in
most patients, without major rejection complications. The
HCV recurrence rate was similar in both groups, although
signiﬁcantly lower HCV RNA loads were obtained with ATG
pretreatment. The mean time to histological recurrence was
shorter in ATG-treated patients but no signiﬁcant diﬀerence
was observed in mean Ishak’s histologic grading and staging
of HCV recurrence.
These studies continue to reinforce the importance of
ATG as a steroid-sparing agent during the induction phase
of LT and for the treatment of ACR. Furthermore, ATG does
not appear to have a signiﬁcant impact on HCV recurrence
andisalsomuchbettertoleratedthanmonoclonalantibodies
such as OKT3. These properties of ATG, together with an
absence nephrotoxicity, had endeared many LT programs to
adopt its use-clinical trials in LT are currently underway to
study if ATG induction plus tacrolimus, MMF and CS versus
standardofcareplus tacrolimus,MMFandCSwillimpactof
renal function and HCV recurrence.
13. Alemtuzumab/Campath-1H
Alemtuzumab or campath-1H (C-1H) is a humanized,
recombinant anti-CD52 monoclonal antibody. It targetsJournal of Transplantation 13
antigen CD52, a cell surface glycoprotein, expressed on more
than 95% of peripheral blood lymphocytes (T cells greater
than B cells), monocytes, macrophages, and natural killer
cells [103]. Alemtuzumab produces profound depletion of
circulating lymphocytes but spares stem cells this may
last approximately one month and lymphocyte recovery,
especially CD4 cells, is slow [104]. A further distinguishing
feature of alemtuzumab is its ability to deplete lymphocytes
from both the blood and lymph nodes with the exception
of plasma and memory cells [105]. The rationale for its
initial use was to facilitate lower doses of maintenance
immunosuppression while higher doses of alemtuzumab
were subsequently used to induce tolerance and eliminate
maintenance immunosuppression [106]. Although alem-
tuzumab alone caused profound lymphocyte and monocyte
depletion, it did not prevent the development of ACR
[107].
The University of Miami reported their experience with
alemtuzumabinductioncombinedwithlow-dosetacrolimus
alone in LT recipients [108]. This group was compared
with patients receiving standard doses of tacrolimus and CS.
Alemtuzumab induction resulted in signiﬁcantly improved
renal function compared with the control subjects. Although
the incidence of ACR was signiﬁcantly lower with alem-
tuzumab induction in the ﬁrst two months (15% in the
study group versus 46% in the control group) after LT, the
median time to rejection was longer with the majority of
ACR episodes occurring after two months. This was most
likely related to the time it took lymphocyte counts to
recover from alemtuzumab. The overall incidence of ACR
was not signiﬁcantly diﬀerent between the two groups (46%
in the alemtuzumab group vs. 55% in control subjects)
although alemtuzumab-related side eﬀects were minimal.
Further studies have focused on its use in combination
with other low-dose immunosuppressive therapy but only
in the presence of CNI’s as alemtuzumab monotherapy was
associated with a high incidence of vascular rejection [109].
14.Interleukin-2Receptor Antibodies
14.1. Mechanism of Action. T w oI L - 2r e c e p t o r( I L - 2 R )
monoclonal antibodies in clinical use are basiliximab
(Simulect, Novartis) and daclizumab (Zenapax, Hoﬀman-La
Roche)) which are chimeric Ig G1 monoclonal antibodies
(daclizumab is 90% human and 10% murine) produced by
recombinant DNA technology. Their chimeric structure ren-
ders these agents less immunogenic than other monoclonal
a n t i b o d i e ss u c ha sO K T 3 .T h eI L - 2r e c e p t o ri sc o m p o s e do f
three noncovalently bound chains: CD25 (a 55 kilodalton
kD alpha chain); a 75kD beta chain and a 64kD gamma
chain.BothagentsengagethealphachainoftheIL-2receptor
(also referred to as CD25 or T cell activation antigen)
which is upregulated in activated T lymphocytes, resulting in
internalization of the T cell receptor. As CD25 is not involved
in transmembrane signaling, antibodies to the alpha chain
will not result in agonist eﬀects [110]. Although IL-2 is still
able to bind to its receptor, this aﬃnity is greatly reduced
leading to inhibition of T cell proliferation in response to
circulating IL-2 (or inhibition of Signal 3 of the T cell
activation pathway).
14.2. Pharmacokinetics and Pharmacodynamics. The half-life
of basiliximab is 7.2 days with a volume of distribution
in adults 8.6 ± 4.1liters and clearance of 41mL/min.
Daclizumab has an estimated half-life of 20 days and a vol-
ume of distribution between 0.032 and 0.043liters/kilogram.
Half-life and volume of distribution are decreased in LT
recipients compared to renal transplant recipients due to a
higher volume of distribution in patients with ascites and
increased immunoglobulin clearance from hypersplenism
[111]. The receptor suppressive eﬀects of basiliximab persist
for 3–4 weeks while those of daclizumumab last for up to 10
weeks.
14.3. Clinical Use. The role of IL-2R monoclonal antibodies
in LT continues to evolve. Early studies used these agents
primarily to reduce or avoid the use of CNI’s (particularly
in patients with renal dysfunction) or to eliminate corti-
costeroid use entirely. Early trials comparing basiliximab
combined with Csa, AZA, and CS or used with Csa and
steroids were associated with an ACR rate of 35% [112, 113].
It was suggested this high rate was related to activated T cells
bypassing CD25 blockade as immunohisochecmical staining
demonstratedthepresenceofactivatedTcellsinﬁltrating the
hepatic allograft [114]. To evaluate the impact of basiliximab
on HCV recurrence in which the primary end point was
histological recurrence of HCV at 12 months, Filliponi et al.
randomized 140 patients to basiliximab and steroids versus
basiliximab and placebo followed by Csa and AZA in both
groups [115]. Histological recurrence (deﬁned as an Ishak
score greater than 12) was 41.2% with basiliximab and
steroids versus 37.5% with basiliximab and placebo (P =
.354) together with a lower treatment failure rate in the
steroid group. A prospective study with long-term follow-up
by Schmeding et al. revaluated the incidence of ACR, graft
and patient survival in patients treated with basiliximab plus
CNI’s and steroids (n = 51) versus CNI’s and steroids (n =
48) [116]. The investigators did not detect a diﬀerence in
these primary end points between the two groups except for
a modest improvement in renal function in the basiliximab
group.
Several studies have reported that the combination of
daclizumab induction with delayed low-dose TAC is safe
and eﬀective in patients with renal dysfunction [117, 118].
However, current data suggests daclizumab should not be
used without CNI’s. Hirose et al. reported ACR of 100% in
CNI naive patients when comparing daclizumab, MMF and
steroids versus daclizumab, MMF and delayed CNI [119].
57.1% of these patients developed steroid-resistant rejection
requiringOKT3.Possibleexplanationsforthehighincidence
of rejection, which remain to be proven, included increased
elimination in ascites which may have contributed to the
short half-life compared to renal transplant recipients in
which the half-life is usually between three and four weeks.
To evaluate the impact of daclizumab on ﬁbrosis from
HCV recurrence at 1 year, Kato el at. randomized patients to14 Journal of Transplantation
tacrolimus and daclizumab (steroid-free) versus tacrolimus
and CS during 1999–2001 and then tacrolimus, MMF and
daclizumab (steroid-free) versus. tacrolimus, MMF and CS
during 2002–2005 [120]. No noticeable diﬀerences in mean
ﬁbrosis stage between the two treatment arms. The incidence
of ACR during the ﬁrst year was the only factor associated
with a signiﬁcantly increased ﬁbrosis stage at 1 year (P =
0.0003); stage two or greater was seen in 63% (17 of
27) versus. 19% (8 of 43) of those with versus to those
without rejection. In addition, MMF use was associated with
signiﬁcantlyfewerpatientsexperiencingACRduringtheﬁrst
six and 12 months post-LT (P = .006 and .046, resp.).
Post-LT diabetes mellitus occurred in 10% versus 45%, and
wound infection in 6% versus 31% of steroid-free versus CS
patients (P = 0.003 and 0.01, respectively). The authors
concluded that although patients tolerated the steroid-free
protocol with fewer side eﬀects, its use had no apparent
impact on hepatic ﬁbrosis progression. The occurrence of
ACR rejection was strongly associated with increased hepatic
ﬁbrosis at one year.
Klintmalm et al. recently reported results of a two-year
prospective randomized study evaluating the impact of IS
on recurrent HCV progression and incidence of rejection
[121]. Recurrent HCV was deﬁned as the presence of at
least grade three inﬂammation or at least stage twp ﬁbrosis
in liver biopsies performed within the ﬁrst year according
to the classiﬁcation described by Batts and Ludwig. The
investigatorsrandomized312patientstothreearms:armone
(n = 80): tacrolimus plus prednisone; arm two (n = 79):
tacrolimus plus prednisone plus MMF; arm three (n = 153);
daclizumab plus tacrolimus plus MMF. Protocol biopsies
were performed at 90, 365, and 720 days. At the two
year follow-up, there was no statistical diﬀerence in the
incidence of rejection, HCV RNA viremia, HCV recurrence,
patient survival, or graft survival among the three groups.
However, more accelerated HCV recurrence was observed
between years one and two in arms one and two. The
investigators concluded that although HCV recurrence at
two years was not inﬂuenced by IS, the rate of progression in
yeartwomayhavebeeninﬂuencedbysteroidsandMMFand
recommended longer-term follow-up evaluation for these
patients.
Until adequately powered randomized controlled trials
areperformed,theuseofIL-receptorantibodiesinLTshould
be used with caution and under the rigor of a clinical
trial, Although these agents are generally welltolerated,
they are expensive, have yet to show a clear beneﬁt over
standardtreatmentandnotrecommendedforroutineusefor
induction therapy.
15. ImmunosuppressantsinDevelopment
CNI’s remain the most widely used medications for mainte-
nancetherapy.However,duetotheirwell-knownsideeﬀects,
a variety of alternatives have been considered in an attempt
to either minimize or possibly abolish its use entirely. Most
of the studies that have evaluated these newer immunosup-
pressives have been conducted in renal transplant recipients
Table 4: Investigational immunosuppressive agents in liver trans-
plantation.
Immunosuppressive
agent Target pathway
FK778 Interferes with pyrimidine metabolism
and DNA synthesis
JAK inhibitors Interfere with Signal 3 transduction
FTY720
Inhibits T cell migration to venule
endothelial cells in secondary
lymphoid tissue
LEA29Y Interferes with Signal 2 via inhibition
of B7/CD28 interaction
—only when promising results are obtained are such trials
repeated in LT recipients. Nonetheless, it is important for
health care professionals responsible for the care of LT
patients to be at least aware of some of the latest and most
promising drugs being studied today in the event they may
provide us with a CNI-free era in the future (Table 4).
16. FK 778
FK778 (Astellas, Osaka, Japan) is a synthetic malononitril-
amide derived from an active metabolite of leﬂunomide,
an isoxazole derivative with anti-inﬂammatory, immuno-
suppressive and antiproliferative properties [122, 123]. It
binds to dihydro-orotate dehydrogenase and inhibits de
novo pyrimidine biosynthesis, thus blocking B- and T-cell
proliferation and also strongly suppresses IgG and IgM anti-
body production [124] It possesses antiviral properties and
can inhibit cytomegalovirus and polyoma virus replication
in vitro [125]. A vasculoprotective eﬀect with inhibition
of neointima formation, thought to be associated with
inhibition of tyrosine kinase and platelet derived growth
factor stimulated smooth muscle proliferation, has also
been reported in animal studies [126]. Pharmacokinetic
studies have shown almost 100% bioavailability with rapid
absorption after oral administration. FK778 is metabolized
mainly in the liver and only a fraction of drug is excreted
unchanged in the urine.
Phase 1 (United States) and phase 2 (Europe) renal
transplantation trials have shown that administration with
tacrolimus and CS is associated with a reduced rate of
ACR [12]. Anemia is the most common side eﬀect which
is reversible with dose reduction and/or discontinuation.
Studies on LT patients are currently being conducted in
Europe.
17.JAK3 Inhibitors
Janus (named after the two-faced God of Gates, Janus)
activated kinases (JAK’s) are vital intermediaries between
cytokine receptors and signal transcription and activation
of transduction (STAT), which result in activation of the
immune cells [127]. JAK-1 and JAK-2 are activated by a
broad range of cytokines that use gp130 whereas JAK-3Journal of Transplantation 15
which is highly expressed in lymphoid cells is activated
only by cytokines that bind to gamma-chain-containing
receptors. These cytokines include IL-2, IL-4, IL-7, IL-
9, IL-15, and IL-21. Stimulation of JAK-3, a cytoplasmic
tyrosinekinase,leadstodimerizationofSTAT5transcription
factor which is speciﬁc for the IL-2 family of cytokines and
hence make this a potential target for immunosuppressive
drugs [128]. The potential for IS by JAK3 inhibitors was
discovered serendipitously by the observation gamma-chain
mutations of JAK3 were associated with severe combined
immunodeﬁciency in humans, a condition associated with
non functional B cells and an absence of T cells and natural
killer (NK) cells.
However, several concerns exist with JAK3 inhibition.
Firstly, loss of NK cells and down regulation of IL-15
transmission may lad to impaired innate immunity and
memory. JAK3 is also homologous with JAK2 which medi-
atessignallingbyhematopoieticcytokinespotentiallyleading
to anemia, leucopenia, and thrombocytopenia [129]. CP-
690,550, a JAK3 inhibitor, is currently undergoing phase 2
trials in renal transplant recipients versus tacrolimus with
all patients also being maintained on MMF and steroids.
It is anticipated encouraging results from these studies will
lead to randomized studies in LT recipients. A number of
JAK inhibitors, with varying degrees of speciﬁcity for JAK-3,
are under investigation [130, 131]. Speciﬁc JAK-3 inhibitors,
which have demonstrated immunosuppressive activity in
small animal models, exhibit fewer of the hematological side
eﬀects seen with those agents that also inhibit JAK-2.
18. FTY 720
FTY 720 represents a new class of immunosuppressive agent
that alters cellular homing patterns. It is a synthetic analogue
of sphingosine which is isolated from the ascomycete Isaria
sinclairi. It shares structural and functional homology with
sphingosine-1-phosphate (SIP), a natural ligand of several
G-protein coupled receptors. It decreases the number of
circulatingbloodlymphocyteswithlymphocytecountsreach
less than 30% of baseline value within 72 hours of treatment.
FTY 720 monophosphate (FTY 720-P), the active form
of the drug, acts as a high aﬃnity agonist at the G-
protein-coupled SIP receptor family, particularly SIP-1 and
SIP-5, on lymphocytes and thymocytes inducing aberrant
receptor internalization,. This renders the cells unresponsive
to the serum lipid SIP-1 receptor and although these cells
remain functional, they are sequestered to the lymphoid
compartment and unable to migrate to inﬂammatory tissues
such as graft sites [132]. There are also studies that suggest
that FTY 720 may provide a level of protection from
ischemia/reperfusion injury in livers [133].
Its major side eﬀect identiﬁed in phase one and two trials
was a negative chronotropic eﬀect, possibly a direct eﬀect of
the drug on the sinus node, and exacerbated in the presence
of beta-blockade. FTY 720 failed phase three clinical trials
and is no longer in clinical development in transplantation.
Despite these concerns, this pathway merits attention as it
remains a potential target for immunosuppressive drugs.
19. Belatacept-Costimulatory SignalBlockade
Signal 2 is a costimulatory signal in T cell activation
representing ligation of a receptor on a T cell with its
ligand on an antigen-presenting cell. Failure to activate
this co-stimulatory pathway leads to T cells becoming
immunologicallyunresponsive—theyareunabletoreplicate,
secrete inﬂammatory cytokines and undergo apoptosis.
One of the best studied co stimulatory pathways is the
interaction between the T cell receptor CD28 with CD80
(B 7-1) and CD86 (B 7-2) on the APC. The homologue to
CD28 is CTLA4 which is transiently expressed after T cell
activation and negatively regulates T cell activation. CTLA4
competetively inhibits binding of CD28 to CD80 and 86.
Trials of CTLA4Ig, a soluble recombinant immunoglob-
ulin fusion protein composed of the extracellular frag-
ment of CTLA4 and the Fc portion of immunoglobulin
G1, were abandoned due to disappointing results in non
human primate models. This led to the development of
belatacept (LEA29Y), a modiﬁed version of CTLA4-Ig with
greater aﬃnity to CD80 and CD86 that is conveniently
administered monthly [134]. Belatacept consists of a soluble
recombinant immumoglobulin fusion protein comprised of
the extracellular CTLA-4 domain and the Fc portion of
immunoglobulin G1.binds to CD80 and CD86 at least four
times more potently than its parent compound and has
demonstrated at least ten time more potent inhibition of T
cell activation in vitro. A recent study compared belatacept
versus Csa in combination with CS, MMF and basiliximab
in 218 renal transplant recipients [135]. At six months,
there was no signiﬁcant diﬀerence in the incidence of ACR
betweenbothgroupsbutrenalfunctionandchronicallograft
nephropathy were signiﬁcantly better in patients in the
belatacept arm. Hypertension and metabolic complications
such as hyperlipidemia and post-transplant hyperglycemia
were also less common in the belatacept arm. Concerns that
concomitant administration of CNI or steroids antagonize
the tolerogenic eﬀect of costimulatory blockade remain
theoretical at present and hopefully future studies in LT will
put these concerns to rest.
20. Summary
Rapid advances in the development of immunosuppressive
medications promises that the future of LT will continue to
be bright. However, in parallel with these discoveries are an
urgent need to perform well-designed randomized studies
and also to consider the emerging role of pharmacogenomics
which has quickly played an important role in the use of
drugs such a AZA. It is likely that recurrent HCV will
continue to play a pivotal role in LT for the foreseeable future
and transplant professionals will need to be aware of the
impact future drugs may have on this disease.
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